Glaucoma surgery methods and systems

• US 8,679,089 B2
• Filed: 10/17/2007
• Issued: 03/25/2014
• Est. Priority Date: 05/21/2001
• Status: Expired due to Term

• Current Assignee: Michael S. Berlin
• Original Assignee: Michael S. Berlin
• Inventors: Berlin, Michael S.
• Primary Examiner(s): Bosworth, Kami A
• Application Number:
  US11/874,179
• Publication Number:
  US 20080082078A1
• Time in Patent Office: 2,351 Days
• Field of Search: 604/21, 604/31, 604/65, 604/66, 604/294, 604/503, 604/521, 600/452, 606/6
• US Class Current: 604/521
• CPC Class Codes: A61F 2009/00844 Feedback systems
• CPC Class Codes: A61F 2009/00868 Ciliary muscles or trabecular meshwork
• CPC Class Codes: A61F 2009/00891 Glaucoma
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61F 9/00802 for photoablation

Abstract

Methods and systems are disclosed for creating an aqueous flow pathway in the trabecular meshwork, juxtacanalicular trabecular meshwork and Schlemm'"'"'s canal of an eye for reducing elevated intraocular pressure. Some embodiments described apparatus and methods useful in photoablation of tissues. In some embodiments, a photoablation apparatus is used to perforate a tissue, forming an aperture into a space behind the tissue. Gases formed during a photoablation process can be used to pressurize the space behind the tissue to enhance patency of the space. In some embodiments the tissue is the trabecular meshwork of the eye and a wall of Schlemm'"'"'s canal, and the space behind the tissue is a portion of the lumen of Schlemm'"'"'s canal. In some embodiments, the method is useful in the treatment of glaucoma by improving outflow from the anterior chamber of the eye into Schlemm'"'"'s canal, reducing intraocular pressure.

Claims

1. A method of guiding a glaucoma surgery, comprising:

advancing a distal portion of a treatment device through an anterior chamber of an eye to a location adjacent Schlemm'"'"'s canal of the eye, the treatment device having an optical waveguide for receiving light at the distal portion of the treatment device; and

identifying the location of Schlemm'"'"'s canal by detecting the presence of blood in Schlemm'"'"'s canal using optical spectroscopy applied to light transmitted by the optical waveguide.

2. The method of claim 1 wherein:

an aperture is created through a first layer of eye tissue at a target site located in the anterior portion of the eye;

advancing the distal portion of the treatment device through the first layer of eye tissue to a location between the first layer of eye tissue and a second layer of eye tissue, the location being within a space between the first layer and second layer of eye tissue, a distal opening of the treatment device being in fluid communication with the space between the first and second layers of eye tissue;

advancing, through the distal portion of the treatment device, a fluid toward the distal opening of the treatment device; and

administering, through the distal opening of the treatment device, the fluid into the space between the first and second layers of eye tissue;

wherein the administering of the fluid expands the space between the first and second layers of eye tissue as the first layer of eye tissue is further separated from the second layer of eye tissue by deposition of the fluid into the space; and

wherein the administering of the fluid is adapted to result in a lowered intraocular pressure in the eye.

3. The method of claim 2, wherein the space comprises a natural space.

4. The method of claim 2, wherein the lowered intraocular pressure is achieved by keeping the aperture open.

5. The method of claim 4, wherein the eye tissue comprises at least the trabecular meshwork.

6. The method of claim 4, wherein the eye tissue comprises a wall of Schlemm'"'"'s canal.

7. The method of claim 2, wherein an angiostatic agent is delivered to the space and the lowered intraocular pressure is achieved by a pharmacological effect of the angiostatic agent.

8. The method of claim 7, wherein the pharmacological effect comprises an anti-inflammatory effect.

9. The method of claim 2, wherein the lowered intraocular pressure is achieved by keeping the aperture in the eye tissue open by a pharmacologic action of an angiostatic agent delivered to the Schlemm'"'"'s canal.

10. The method of claim 9, wherein the angiostatic agent-comprises anecortave acetate.

11. The method of claim 9, wherein the angiostatic agent is an angiostatic steroid and the lowered intraocular pressure is achieved by a pharmacologic action of the angiostatic steroid.

12. The method of claim 2, wherein the fluid comprises a viscoelastic fluid.

13. The method of claim 12, wherein the viscoelastic fluid comprises molecules having a molecular size that is larger than a pore size of the first layer of eye tissue.

14. The method of claim 2, wherein creating the aperture comprises cutting the first layer of eye tissue with a cutting device.

15. The method of claim 2, wherein the fluid flows through the treatment device under positive pressure.

16. The method of claim 2, wherein the fluid is advanced through a fluid pathway coxial with the treatment device.

17. The method of claim 2, wherein the first layer of eye tissue comprises the trabecular meshwork, the second layer of tissue comprises a portion of an outer wall of Schlemm'"'"'s canal, and the space comprises a portion of lumen of Schlemm'"'"'s canal.

18. The method of claim 1, further comprising:

advancing the distal portion of the treatment device through the anterior chamber of the eye toward the trabecular meshwork; and

creating an aperture in the trabecular meshwork using the treatment device.

19. The method of claim 1 further comprising:

creating an aperture through a first layer of eye tissue at a target site located in an anterior portion of the eye;

advancing a distal portion of the treatment device through the first layer of eye tissue to a location between the first layer of eye tissue and a second layer of eye tissue, the location being within a space between the first layer and second layer of eye tissue, a distal opening of the treatment device being in fluid communication with the space between the first and second layers of eye tissue;

advancing, through the distal portion of the treatment device, a fluid toward the distal opening of the treatment device; and

administering, through the distal opening of the treatment device, the fluid into the space between the first and second layers of eye tissue;

wherein the administering of the fluid expands the space between the first and second layers of eye tissue as the first layer of eye tissue is thinned by deposition of the fluid in the space;

wherein the administering of the fluid is adapted to result in a reduced intraocular pressure in the eye.

20. The method of claim 1, further comprising creating an aperture in the trabecular meshwork of the eye adjacent to the location of the blood in Schlemm'"'"'s canal.

21. The method of claim 1 wherein the treatment device comprises:

a laser that produces a beam used to ablate a region of a trabecular meshwork of the eye; and

a delivery system that directs the beam from within the eye to the trabecular meshwork of the eye, said delivery system directing one or more gas bubbles in the eye through the trabecular meshwork and into Schlemm'"'"'s canal of the eye.

22. The apparatus of claim 21, further comprising a sensor coupled to the delivery system, the sensor being configured to detect contact of a portion of the treatment device with a surface of the trabecular meshwork.

23. The apparatus of claim 21, wherein the delivery system comprises a hood to direct the one or more gas bubbles through the trabecular meshwork.

24. The apparatus of claim 21, further comprising a gas injector module, said gas injector module configured to inject a gas from outside the eye into an aperture formed in the trabecular meshwork and into Schlemm'"'"'s canal.

25. The apparatus of claim 21, further comprising a sensor module that is configured to detect patency of an aperture formed in the trabecular meshwork.

26. The apparatus of claim 25, wherein the sensor module is configured to detect a gas bubble that moves from or to Schlemm'"'"'s canal through the aperture.

27. The method of claim 1 wherein the treatment device comprises:

a laser device configured to deliver ablative laser light to the trabecular meshwork tissue of the eye to create an aperture in the trabecular meshwork; and

a contact sensor that detects contact of the laser device with the trabecular meshwork;

wherein the laser device directs gas bubbles through the aperture in the trabecular meshwork into Schlemm'"'"'s canal.

28. The method of claim 1 further comprising:

creating an aperture in eye tissue, the eye tissue comprising one or more of trabecular meshwork, juxtacanalicular trabecular meshwork, an inner wall of Schlemm'"'"'s Canal and Schlemm'"'"'s Canal;

forming a gas bubble within the eye by ablation of the eye tissue; and

directing the gas bubble from within the eye tissue through the aperture and into one or more of Schlemm'"'"'s Canal, collector channels or another natural outflow pathway of the eye, thereby modifying the natural outflow pathway.

29. The method of claim 28, wherein the natural outflow pathway comprises an episcleral vein of the eye.

30. The method of claim 1, comprising:

photoablating tissue of the eye at a first treatment site, resulting in the formation of a first aperture in the eye tissue;

photoablating the eye tissue at a second treatment site, resulting in the formation of a second aperture in the eye tissue; and

forming gas bubbles within the eye by ablation of eye tissue;

directing the gas bubbles from within the anterior chamber and from within the trabecular meshwork of the eye through the first aperture and into a natural aqueous outflow pathway of the eye; and

detecting the presence of one or more of the gas bubbles after the one or more gas bubble moves through the natural aqueous outflow pathway through the second aperture and into the anterior chamber.

31. The method of claim 30, wherein the eye tissue comprises a trabecular meshwork of the eye, and the natural aqueous outflow pathway comprises Schlemm'"'"'s canal of the eye.

32. The method of claim 1 further comprising:

providing a volume of gas that comprises a therapeutic agent; and

directing the volume of gas into an eye to alter, move, or separate structures within the eye.

33. The method of claim 1, wherein detection of blood in Schlemm'"'"'s canal using optical spectroscopy comprises detecting the presence of hemoglobin based on its absorption spectrum.

34. The method of claim 1, wherein detection of blood in Schlemm'"'"'s canal using optical spectroscopy comprises the presence of a marker substance.

35. The method of claim 34, wherein detection of blood in Schlemm'"'"'s canal using optical spectroscopy comprising the presence of a marker substance includes providing a fluorescent material as the marker substance.

36. The method of claim 34, wherein the material comprises at least one of the fluorescein, idocyanine green and trypan blue.

37. The method of claim 1, further comprising providing an optical waveguide that extends from the distal end of the treatment device disposed within the eye to an optical spectroscopy instrument located exterior to the eye.

38. A method, of performing glaucoma surgery, comprising:

advancing a distal portion of a treatment device through an anterior chamber of an eye to a location adjacent Schlemm'"'"'s canal of the eye, the treatment device having an optical waveguide for receiving light at the distal portion of the treatment device;

penetrating an inner wall of Schlemm'"'"'s canal with a distal end of the treatment device; and

detecting penetration of the inner wall of Schlemm'"'"'s canal by detecting the presence of blood in Schlemm'"'"'s canal using optical spectroscopy applied to light transmitted by the optical waveguide.

39. The method of claim 38 wherein the penetrating the inner wall of Schlemm'"'"'s canal is by advancing a distal portion of the treatment device through a first layer of eye tissue to a location between the first layer of eye tissue and a second layer of eye tissue and creates an aperture through the first layer of eye tissue at a target site located in an anterior portion of the eye,

a distal opening of the treatment device being a fluid communication with the space between the first and second layers of eye tissue;

advancing, through a distal portion of the treatment device a fluid; and

administering, through the distal opening of the treatment device, the fluid into the space between the first and second layers of eye tissue;

wherein administering of the fluid expands the space between the first and second layers of eye tissue and compresses the first layer of eye tissue causing thinning of the first layer.

40. The method of claim 39, wherein the method is repeated to form multiple apertures, the multiple apertures resulting in a lowering of intraocular pressure.

41. The method of claim 40 further including the delivery of a angiostatic agent resulting in reduction of intraocular pressure in the eye and maintenance of the patency of the apertures.

42. The method of claim 39, wherein the fluid comprises a gas or a viscoelestaic fluid.

43. The method of claim 42, wherein the viscoelastic fluid comprises molecules having a molecular size that is larger than a pore size of the first layer of eye tissue.

44. A method, of guiding glaucoma surgery, comprising:

advancing a distal portion of a treatment device through an anterior chamber of an eye to a location adjacent Schlemm'"'"'s canal of the eye, the treatment device having a physical-state-changing contact sensor disposed at a distal end thereof; and

advancing the treatment device until the contact sensor senses contact of the distal end of the treatment device with the trabecular meshwork of the eye.

45. The method of claim 44, further comprising, after contact by the distal end with the trabecular meshwork, advancing the distal end of the treatment device so as to compress the trabecular meshwork.

46. The method of claim 44, further comprising, after contact by the distal end with the trabecular meshwork, enabling initiation of tissue photoablation process.

47. The method of claim 44, further comprising, after contact by the distal end with the trabecular meshwork, advancing the treatment device while photoablating tissue in front of the distal end of the treatment device.

48. A method of performing glaucoma surgery, comprising:

photoablating tissue between the anterior chamber of the eye and Schlemm'"'"'s canal at a first treatment site, resulting in the formation of a first aperture in the eye tissue;

photoablating the eye tissue between the anterior chamber of the eye and Schlemm'"'"'s canal at a second treatment site in the eye thereby forming gas bubbles; and

detecting penetration of an inner wall of Schlemm'"'"'s canal by observing one or more gas bubbles moving from within Schlemm'"'"'s canal through a natural aqueous outflow pathway provided by the first aperture and into the anterior chamber.

49. A method, of performing glaucoma surgery, comprising:

advancing a distal portion of a treatment device through an anterior chamber of an eye to a location adjacent Schlemm'"'"'s canal of the eye, the treatment device having an acoustic waveguide for receiving acoustic energy at the distal portion of the treatment device;

penetrating an inner wall of Schlemm'"'"'s canal with a distal end of the treatment device; and

detecting penetration of the inner wall of Schlemm'"'"'s canal by photoacoustic spectroscopy applied to acoustic energy transmitted by the acoustic waveguide.